Cargando…
The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages
BACKGROUND: Immunosenescence, the age-related decline of immunity, affects the immune responses of non-small cell lung cancer (NSCLC) patients. Through immune responses, programmed death-1 (PD-1) inhibitors exert their antitumor robustness. In different ages of NSCLC patients, especially the older p...
Autores principales: | Wu, Yingcheng, Ju, Qianqian, Qian, Bei, Zhang, Feng, Shi, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814271/ https://www.ncbi.nlm.nih.gov/pubmed/29487704 http://dx.doi.org/10.18632/oncotarget.23678 |
Ejemplares similares
-
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature
por: Norum, Jan, et al.
Publicado: (2018) -
Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2023) -
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
por: Cao, Xiaobo, et al.
Publicado: (2017) -
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
por: Jiang, Liyan, et al.
Publicado: (2017) -
PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)